Epitalon vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Epitalon
Epitalon (Epithalon) is a synthetic tetrapeptide based on the natural peptide epithalamin, produced by the pineal gland. It is primarily studied for its effects on telomerase activation.
Full details →Retatrutide
Retatrutide (LY3437943) is a first-in-class triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. Developed by Eli Lilly, it is currently in Phase 3 clinical trials and has demonstrated the highest weight loss of any obesity medication to date — up to 28.7% body weight reduction at 48 weeks. The triple-receptor mechanism represents the next evolution beyond dual agonists like tirzepatide.
Full details →Side-by-Side Comparison
| Aspect | Epitalon | Retatrutide |
|---|---|---|
| Mechanism | Stimulates telomerase production, which can lengthen telomeres on DNA strands. May also regulate melatonin production and circadian rhythms. | Retatrutide is a synthetic peptide that activates three incretin/metabolic hormone receptors: (1) GLP-1 receptor — appetite suppression, insulin secretion, delayed gastric emptying, (2) GIP receptor — enhanced insulin sensitivity, improved fat metabolism, (3) Glucagon receptor — increased energy expenditure, hepatic fat mobilization, thermogenesis. The glucagon receptor component is the key differentiator, adding an energy-expenditure mechanism absent from GLP-1 and dual GIP/GLP-1 agonists. The molecule uses a C20 fatty diacid for albumin binding, enabling once-weekly dosing. |
| Typical Dosage | Typical protocols: 5-10mg daily for 10-20 days, repeated 2-3 times per year. | Phase 2 trial doses: 0.5 mg, 4 mg, 8 mg, and 12 mg weekly. The 12 mg dose produced maximum weight loss (28.7%). Phase 3 trials are evaluating doses up to 12 mg. Dose escalation schedule similar to other GLP-1s (start low, increase every 4 weeks). Final approved dosing not yet established — Phase 3 trials ongoing. |
| Administration | Subcutaneous or intramuscular injection. Usually administered in cycles rather than continuously. | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled single-dose pens. Not yet commercially available — estimated FDA approval ~2027-2028. |
| Side Effects | Generally well-tolerated. May affect sleep patterns initially. | Phase 2 data: nausea (up to 25%), diarrhea (up to 22%), vomiting (up to 15%), constipation, decreased appetite. GI side effects were dose-dependent and generally mild-to-moderate. Lower rates of nausea compared to semaglutide, potentially due to GIP component. Increased heart rate observed at higher doses. |
| Best For |
Key Differences
Unique to Epitalon:
Unique to Retatrutide:
Detailed Analysis
Commonalities
Epitalon and Retatrutide are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Epitalon for Sleep Quality. Choose Retatrutide for Fat Loss.
Ready to Learn More?
Looking for trusted sources?